Synergy Pharmaceuticals (SGYP) 8-K Synergy Pharmaceuticals to Present at Oppenheimer 28th Annual Healthcare Conference

Exhibit 99.1

Synergy Pharmaceuticals to Present at Oppenheimer 28th Annual
Healthcare Conference

NEW YORK, March 13, 2018 —Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) today announced that Troy Hamilton, Chief Executive Officer of Synergy, will present a corporate update at the Oppenheimer 28th Annual Healthcare Conference on Tuesday, March 20, 2018 at 3:55 p.m. Eastern Time at the Westin New York Grand Central in New York City.

A live webcast of Synergy’s presentation will be accessible through the Investors section of the company’s website at www.synergypharma.com. A replay of the webcast will be available on Synergy’s website for 90 days following the conference.

About Synergy Pharmaceuticals Inc.

Synergy is a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies. The company has pioneered discovery, research and development efforts on analogs of uroguanylin, a naturally occurring and endogenous human GI peptide, for the treatment of GI diseases and disorders. Synergy’s proprietary GI platform includes one commercial product TRULANCE® and a second product candidate, dolcanatide. For more information, please visit www.synergypharma.com.

Company Contact:

Gem Hopkins

VP, Investor Relations and Corporate Communications

212-584-7610

ghopkins@synergypharma.com